$ 38.75 Stock Price

Discussion in 'GlaxoSmithKline' started by anonymous, Nov 15, 2016 at 6:43 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What a POS company we work for. Layoffs to follow.
     

  2. anonymous

    anonymous Guest

    Well friend, iffin' you feel that-a-way, why not quit right now and find something better ? It is as simple as that !
     
  3. anonymous

    anonymous Guest

    Many people have been leaving! Many job changes on LinkedIn every week.

    Great thing about GSK is you are already in a suit to interview and don't have to call off work to either!
     
  4. anonymous

    anonymous Guest

    Emma is having high level meetings and cleaning up US Pharma is high on her agenda. We are bloated and ineffective. If can't compete and sell Breo now, what hope do we have when the generic is out?

    April, Emma is officially in and Andrew is out and she can lay her new framework in place.
     
  5. anonymous

    anonymous Guest

    We need to be thinned. Too any reps and managers.
     
  6. anonymous

    anonymous Guest

    Why would I leave. I make $100,000 a year and work 30 hours a week. Not bad for a 28 year old.
    The truth hurts, I'm not leaving until they throw me out.
     
  7. anonymous

    anonymous Guest

    Maybe one day you will be like many retired reps......sitting in your LazyBoy by the fire wondering what life would have been like in another career, where your full potential could be met, and your full money making power is put to good use.....but you chose sitting in your safe place and taking what they throw you. So sad.
     
  8. anonymous

    anonymous Guest

    its not Emma's fault, she is a perfect choice. The market doesn't understand that it's the SB people that are the prob, not that Emma is a novice in pharma.
     
  9. anonymous

    anonymous Guest

    Not been around long have you ? It is not " SB " , but " SKB " ....the ones who bought you.
     
  10. anonymous

    anonymous Guest

    21 year and joined SB. Only the GW dopes called it skb
     
  11. anonymous

    anonymous Guest

     
  12. anonymous

    anonymous Guest

    Ugghhhh!!! Hate to spoil it for those looking for an exit package. No layoffs next year. Open triple and RA biologic coming. Bro will hit a billion in 2016, Anoro is the LABA/LAMA of choice and growing, and the U.S. has been beating Wall St. expectations. Nope, no layoffs in 2017. Nice try though.
     
  13. anonymous

    anonymous Guest

    But why is GSK stock in steady decline if all is going well? Other big pharma stocks are jumping up in the post Trump victory but GSK is going down. The NY Times article really should have shareholders up in arms over the fact that Witty, who is implicated in the article as being aware or at least grossly ignorant of the China misdeeds. Today the two investigators that were jailed in China are suing GSK for lying that bribery was not occurring. GSK needs to purge Witty and all the Witty/Garnier legacy board members immediately and sue them for incompetence
     
  14. anonymous

    anonymous Guest

    So sad that you must be a corporate shill, how does that make you feel. To be so negative portends a small minded person (not even an individual) who must denigrate for a few sheckles.
     
  15. anonymous

    anonymous Guest

    Thanks for the post Andrew, you will be remembered as an awful CEO. Our stock has gone from $56 to $38 in less than 3 years. Also, I hope the rumor is not true but the severance is going from 2 weeks to 1 year starting in 2018 as internal talk are getting really serious.
     
  16. anonymous

    anonymous Guest

    I have never really understood severance. Why give it or even offer it ?
     
  17. anonymous

    anonymous Guest

    What are you talking about? RA biologic is 16th in class! Open triple isn't even approved yet and will launch in 2018. Anoro market is small and Breo doesn't look like it going to hit its stretch goal. FDA will make a decision on 3 applications that were submitted to the them on generic Advair in February. And the ripple of a generic ICS/LABA will effect the entire market. Tanzeum specialty reps and managers are being rolled into all open positions so there will be no vacancies. So you will have a sales team that is at max capacity selling only Breo and Anoro? Can that be sustained? Nope. Realignments in April to streamline sales force based on FDA's decision. Remember, look at past precedent, has any pharma company been able to withstand a multi-billion dollar product going generic without cuts to sales team? No.
     
  18. anonymous

    anonymous Guest

    Haha 16th? Tanzeum was launched 3rd glp-1 to market and second once weekly to market and look what happened.
     
  19. anonymous

    anonymous Guest

    To post#13 & 16. First, there are no corporate "shills" that you speak of. This is a public forum to open discussion and opinion. Second, GSK stock has fallen with the entire Pharma sector. Yes there are a few companies that have risen recently, but the sector is down. Third, the new RA biologic is innovative and will be used as both mono-therapy and as add-on. This is a billion dollar slam dunk. So please save your lay-off comments for 2019. And even then it's a stretch. Enjoy your families and count your blessings. Ziggy out!
     
  20. anonymous

    anonymous Guest

    3rd in class biologic with single indication. They shall call it DOGUMAB